nodes	percent_of_prediction	percent_of_DWPC	metapath
Arformoterol—CYP2D6—Temsirolimus—kidney cancer	0.114	0.227	CbGbCtD
Arformoterol—CYP2C9—Capecitabine—kidney cancer	0.0683	0.136	CbGbCtD
Arformoterol—CYP2D6—Pazopanib—kidney cancer	0.0599	0.119	CbGbCtD
Arformoterol—CYP2C19—Sorafenib—kidney cancer	0.0457	0.0911	CbGbCtD
Arformoterol—CYP2C9—Paclitaxel—kidney cancer	0.0428	0.0853	CbGbCtD
Arformoterol—CYP2D6—Erlotinib—kidney cancer	0.0428	0.0852	CbGbCtD
Arformoterol—CYP2C9—Sorafenib—kidney cancer	0.038	0.0758	CbGbCtD
Arformoterol—CYP2D6—Sorafenib—kidney cancer	0.0348	0.0693	CbGbCtD
Arformoterol—CYP2D6—Vinblastine—kidney cancer	0.0343	0.0684	CbGbCtD
Arformoterol—CYP2D6—Doxorubicin—kidney cancer	0.0211	0.042	CbGbCtD
Arformoterol—Isoprenaline—MAPK1—kidney cancer	0.00375	0.508	CrCbGaD
Arformoterol—Dobutamine—CA2—kidney cancer	0.00283	0.383	CrCbGaD
Arformoterol—Isoprenaline—CYP1A1—kidney cancer	0.000806	0.109	CrCbGaD
Arformoterol—Connective tissue disorder—Capecitabine—kidney cancer	0.000278	0.0006	CcSEcCtD
Arformoterol—Vomiting—Everolimus—kidney cancer	0.000278	0.000599	CcSEcCtD
Arformoterol—Urethral disorder—Capecitabine—kidney cancer	0.000278	0.000599	CcSEcCtD
Arformoterol—Agitation—Paclitaxel—kidney cancer	0.000276	0.000596	CcSEcCtD
Arformoterol—Rash—Everolimus—kidney cancer	0.000275	0.000594	CcSEcCtD
Arformoterol—Dermatitis—Everolimus—kidney cancer	0.000275	0.000594	CcSEcCtD
Arformoterol—Headache—Vinblastine—kidney cancer	0.000275	0.000593	CcSEcCtD
Arformoterol—Angioedema—Paclitaxel—kidney cancer	0.000274	0.000592	CcSEcCtD
Arformoterol—Headache—Everolimus—kidney cancer	0.000274	0.000591	CcSEcCtD
Arformoterol—Hypotension—Gemcitabine—kidney cancer	0.000274	0.00059	CcSEcCtD
Arformoterol—Body temperature increased—Dactinomycin—kidney cancer	0.000273	0.000589	CcSEcCtD
Arformoterol—Abdominal pain—Dactinomycin—kidney cancer	0.000273	0.000589	CcSEcCtD
Arformoterol—Visual impairment—Capecitabine—kidney cancer	0.000273	0.000589	CcSEcCtD
Arformoterol—Asthenia—Sorafenib—kidney cancer	0.000272	0.000587	CcSEcCtD
Arformoterol—Malaise—Paclitaxel—kidney cancer	0.000271	0.000584	CcSEcCtD
Arformoterol—Hypoglycaemia—Doxorubicin—kidney cancer	0.00027	0.000583	CcSEcCtD
Arformoterol—Hypersensitivity—Sunitinib—kidney cancer	0.000269	0.00058	CcSEcCtD
Arformoterol—Pruritus—Sorafenib—kidney cancer	0.000268	0.000579	CcSEcCtD
Arformoterol—Vomiting—Erlotinib—kidney cancer	0.000268	0.000578	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Gemcitabine—kidney cancer	0.000267	0.000576	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Vincristine—kidney cancer	0.000266	0.000575	CcSEcCtD
Arformoterol—Fatigue—Vincristine—kidney cancer	0.000266	0.000574	CcSEcCtD
Arformoterol—Rash—Erlotinib—kidney cancer	0.000266	0.000573	CcSEcCtD
Arformoterol—Dermatitis—Erlotinib—kidney cancer	0.000265	0.000573	CcSEcCtD
Arformoterol—Palpitations—Paclitaxel—kidney cancer	0.000265	0.000573	CcSEcCtD
Arformoterol—Insomnia—Gemcitabine—kidney cancer	0.000265	0.000571	CcSEcCtD
Arformoterol—Headache—Erlotinib—kidney cancer	0.000264	0.00057	CcSEcCtD
Arformoterol—Constipation—Vincristine—kidney cancer	0.000264	0.000569	CcSEcCtD
Arformoterol—Pain—Vincristine—kidney cancer	0.000264	0.000569	CcSEcCtD
Arformoterol—Cardiac disorder—Capecitabine—kidney cancer	0.000263	0.000567	CcSEcCtD
Arformoterol—Cough—Paclitaxel—kidney cancer	0.000262	0.000566	CcSEcCtD
Arformoterol—Asthenia—Sunitinib—kidney cancer	0.000262	0.000565	CcSEcCtD
Arformoterol—Dyspnoea—Gemcitabine—kidney cancer	0.000261	0.000563	CcSEcCtD
Arformoterol—Nausea—Vinblastine—kidney cancer	0.00026	0.000562	CcSEcCtD
Arformoterol—Somnolence—Gemcitabine—kidney cancer	0.00026	0.000562	CcSEcCtD
Arformoterol—Nausea—Everolimus—kidney cancer	0.000259	0.00056	CcSEcCtD
Arformoterol—Diarrhoea—Sorafenib—kidney cancer	0.000259	0.00056	CcSEcCtD
Arformoterol—Hypertension—Paclitaxel—kidney cancer	0.000259	0.00056	CcSEcCtD
Arformoterol—Pruritus—Sunitinib—kidney cancer	0.000258	0.000557	CcSEcCtD
Arformoterol—Immune system disorder—Capecitabine—kidney cancer	0.000256	0.000552	CcSEcCtD
Arformoterol—Chest pain—Paclitaxel—kidney cancer	0.000256	0.000552	CcSEcCtD
Arformoterol—Myalgia—Paclitaxel—kidney cancer	0.000256	0.000552	CcSEcCtD
Arformoterol—Arthralgia—Paclitaxel—kidney cancer	0.000256	0.000552	CcSEcCtD
Arformoterol—Mediastinal disorder—Capecitabine—kidney cancer	0.000255	0.000551	CcSEcCtD
Arformoterol—Anxiety—Paclitaxel—kidney cancer	0.000255	0.00055	CcSEcCtD
Arformoterol—Hypersensitivity—Dactinomycin—kidney cancer	0.000254	0.000549	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.000254	0.000548	CcSEcCtD
Arformoterol—Arrhythmia—Capecitabine—kidney cancer	0.000253	0.000546	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Gemcitabine—kidney cancer	0.000253	0.000545	CcSEcCtD
Arformoterol—Discomfort—Paclitaxel—kidney cancer	0.000253	0.000545	CcSEcCtD
Arformoterol—Fatigue—Gemcitabine—kidney cancer	0.000252	0.000545	CcSEcCtD
Arformoterol—Gastrointestinal pain—Vincristine—kidney cancer	0.000252	0.000545	CcSEcCtD
Arformoterol—Dizziness—Sorafenib—kidney cancer	0.000251	0.000541	CcSEcCtD
Arformoterol—Pain—Gemcitabine—kidney cancer	0.00025	0.00054	CcSEcCtD
Arformoterol—Constipation—Gemcitabine—kidney cancer	0.00025	0.00054	CcSEcCtD
Arformoterol—Nausea—Erlotinib—kidney cancer	0.00025	0.00054	CcSEcCtD
Arformoterol—Dry mouth—Paclitaxel—kidney cancer	0.00025	0.00054	CcSEcCtD
Arformoterol—Diarrhoea—Sunitinib—kidney cancer	0.00025	0.000539	CcSEcCtD
Arformoterol—Mental disorder—Capecitabine—kidney cancer	0.000248	0.000535	CcSEcCtD
Arformoterol—Asthenia—Dactinomycin—kidney cancer	0.000248	0.000535	CcSEcCtD
Arformoterol—Malnutrition—Capecitabine—kidney cancer	0.000246	0.000532	CcSEcCtD
Arformoterol—Dehydration—Doxorubicin—kidney cancer	0.000245	0.000529	CcSEcCtD
Arformoterol—Anaphylactic shock—Paclitaxel—kidney cancer	0.000245	0.000529	CcSEcCtD
Arformoterol—Oedema—Paclitaxel—kidney cancer	0.000245	0.000529	CcSEcCtD
Arformoterol—Body temperature increased—Vincristine—kidney cancer	0.000244	0.000526	CcSEcCtD
Arformoterol—Abdominal pain—Vincristine—kidney cancer	0.000244	0.000526	CcSEcCtD
Arformoterol—Infection—Paclitaxel—kidney cancer	0.000244	0.000525	CcSEcCtD
Arformoterol—Dry skin—Doxorubicin—kidney cancer	0.000242	0.000522	CcSEcCtD
Arformoterol—Dysgeusia—Capecitabine—kidney cancer	0.000241	0.000521	CcSEcCtD
Arformoterol—Dizziness—Sunitinib—kidney cancer	0.000241	0.000521	CcSEcCtD
Arformoterol—Feeling abnormal—Gemcitabine—kidney cancer	0.000241	0.000521	CcSEcCtD
Arformoterol—Vomiting—Sorafenib—kidney cancer	0.000241	0.00052	CcSEcCtD
Arformoterol—Nervous system disorder—Paclitaxel—kidney cancer	0.00024	0.000519	CcSEcCtD
Arformoterol—Hypokalaemia—Doxorubicin—kidney cancer	0.00024	0.000518	CcSEcCtD
Arformoterol—Tachycardia—Paclitaxel—kidney cancer	0.000239	0.000516	CcSEcCtD
Arformoterol—Rash—Sorafenib—kidney cancer	0.000239	0.000516	CcSEcCtD
Arformoterol—Dermatitis—Sorafenib—kidney cancer	0.000239	0.000515	CcSEcCtD
Arformoterol—Back pain—Capecitabine—kidney cancer	0.000238	0.000514	CcSEcCtD
Arformoterol—Skin disorder—Paclitaxel—kidney cancer	0.000238	0.000514	CcSEcCtD
Arformoterol—Headache—Sorafenib—kidney cancer	0.000238	0.000513	CcSEcCtD
Arformoterol—Muscle spasms—Capecitabine—kidney cancer	0.000237	0.000511	CcSEcCtD
Arformoterol—Diarrhoea—Dactinomycin—kidney cancer	0.000236	0.00051	CcSEcCtD
Arformoterol—Nasopharyngitis—Doxorubicin—kidney cancer	0.000236	0.000509	CcSEcCtD
Arformoterol—Gastritis—Doxorubicin—kidney cancer	0.000233	0.000504	CcSEcCtD
Arformoterol—Vomiting—Sunitinib—kidney cancer	0.000232	0.000501	CcSEcCtD
Arformoterol—Body temperature increased—Gemcitabine—kidney cancer	0.000231	0.000499	CcSEcCtD
Arformoterol—Tremor—Capecitabine—kidney cancer	0.000231	0.000498	CcSEcCtD
Arformoterol—Rash—Sunitinib—kidney cancer	0.00023	0.000496	CcSEcCtD
Arformoterol—Dermatitis—Sunitinib—kidney cancer	0.00023	0.000496	CcSEcCtD
Arformoterol—Hypotension—Paclitaxel—kidney cancer	0.000229	0.000494	CcSEcCtD
Arformoterol—Ill-defined disorder—Capecitabine—kidney cancer	0.000229	0.000493	CcSEcCtD
Arformoterol—Headache—Sunitinib—kidney cancer	0.000229	0.000493	CcSEcCtD
Arformoterol—Asthma—Doxorubicin—kidney cancer	0.000228	0.000492	CcSEcCtD
Arformoterol—Influenza—Doxorubicin—kidney cancer	0.000228	0.000492	CcSEcCtD
Arformoterol—Hypersensitivity—Vincristine—kidney cancer	0.000227	0.000491	CcSEcCtD
Arformoterol—Nausea—Sorafenib—kidney cancer	0.000225	0.000486	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Paclitaxel—kidney cancer	0.000223	0.000482	CcSEcCtD
Arformoterol—Malaise—Capecitabine—kidney cancer	0.000222	0.00048	CcSEcCtD
Arformoterol—Angina pectoris—Doxorubicin—kidney cancer	0.000222	0.000479	CcSEcCtD
Arformoterol—Insomnia—Paclitaxel—kidney cancer	0.000222	0.000478	CcSEcCtD
Arformoterol—Asthenia—Vincristine—kidney cancer	0.000221	0.000478	CcSEcCtD
Arformoterol—Vomiting—Dactinomycin—kidney cancer	0.00022	0.000474	CcSEcCtD
Arformoterol—Bronchitis—Doxorubicin—kidney cancer	0.000219	0.000473	CcSEcCtD
Arformoterol—Dyspnoea—Paclitaxel—kidney cancer	0.000219	0.000472	CcSEcCtD
Arformoterol—Somnolence—Paclitaxel—kidney cancer	0.000218	0.00047	CcSEcCtD
Arformoterol—Palpitations—Capecitabine—kidney cancer	0.000218	0.00047	CcSEcCtD
Arformoterol—Rash—Dactinomycin—kidney cancer	0.000218	0.00047	CcSEcCtD
Arformoterol—Nausea—Sunitinib—kidney cancer	0.000217	0.000468	CcSEcCtD
Arformoterol—Dyspepsia—Paclitaxel—kidney cancer	0.000216	0.000466	CcSEcCtD
Arformoterol—Cough—Capecitabine—kidney cancer	0.000215	0.000464	CcSEcCtD
Arformoterol—Hypertension—Capecitabine—kidney cancer	0.000213	0.000459	CcSEcCtD
Arformoterol—Upper respiratory tract infection—Doxorubicin—kidney cancer	0.000212	0.000457	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Paclitaxel—kidney cancer	0.000212	0.000457	CcSEcCtD
Arformoterol—Fatigue—Paclitaxel—kidney cancer	0.000211	0.000456	CcSEcCtD
Arformoterol—Diarrhoea—Vincristine—kidney cancer	0.000211	0.000456	CcSEcCtD
Arformoterol—Asthenia—Gemcitabine—kidney cancer	0.00021	0.000453	CcSEcCtD
Arformoterol—Arthralgia—Capecitabine—kidney cancer	0.00021	0.000453	CcSEcCtD
Arformoterol—Chest pain—Capecitabine—kidney cancer	0.00021	0.000453	CcSEcCtD
Arformoterol—Myalgia—Capecitabine—kidney cancer	0.00021	0.000453	CcSEcCtD
Arformoterol—Pain—Paclitaxel—kidney cancer	0.00021	0.000452	CcSEcCtD
Arformoterol—Constipation—Paclitaxel—kidney cancer	0.00021	0.000452	CcSEcCtD
Arformoterol—Anxiety—Capecitabine—kidney cancer	0.000209	0.000451	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.000208	0.00045	CcSEcCtD
Arformoterol—Discomfort—Capecitabine—kidney cancer	0.000207	0.000447	CcSEcCtD
Arformoterol—Pruritus—Gemcitabine—kidney cancer	0.000207	0.000447	CcSEcCtD
Arformoterol—Hyperglycaemia—Doxorubicin—kidney cancer	0.000206	0.000444	CcSEcCtD
Arformoterol—Dry mouth—Capecitabine—kidney cancer	0.000205	0.000443	CcSEcCtD
Arformoterol—Nausea—Dactinomycin—kidney cancer	0.000205	0.000443	CcSEcCtD
Arformoterol—Dizziness—Vincristine—kidney cancer	0.000204	0.00044	CcSEcCtD
Arformoterol—Feeling abnormal—Paclitaxel—kidney cancer	0.000202	0.000436	CcSEcCtD
Arformoterol—Oedema—Capecitabine—kidney cancer	0.000201	0.000434	CcSEcCtD
Arformoterol—Gastrointestinal pain—Paclitaxel—kidney cancer	0.0002	0.000433	CcSEcCtD
Arformoterol—Diarrhoea—Gemcitabine—kidney cancer	0.0002	0.000432	CcSEcCtD
Arformoterol—Infection—Capecitabine—kidney cancer	0.0002	0.000431	CcSEcCtD
Arformoterol—Urinary tract infection—Doxorubicin—kidney cancer	0.000198	0.000426	CcSEcCtD
Arformoterol—Conjunctivitis—Doxorubicin—kidney cancer	0.000198	0.000426	CcSEcCtD
Arformoterol—Nervous system disorder—Capecitabine—kidney cancer	0.000197	0.000426	CcSEcCtD
Arformoterol—Tachycardia—Capecitabine—kidney cancer	0.000196	0.000424	CcSEcCtD
Arformoterol—Vomiting—Vincristine—kidney cancer	0.000196	0.000423	CcSEcCtD
Arformoterol—Skin disorder—Capecitabine—kidney cancer	0.000195	0.000422	CcSEcCtD
Arformoterol—Urticaria—Paclitaxel—kidney cancer	0.000195	0.00042	CcSEcCtD
Arformoterol—Rash—Vincristine—kidney cancer	0.000195	0.00042	CcSEcCtD
Arformoterol—Dermatitis—Vincristine—kidney cancer	0.000194	0.00042	CcSEcCtD
Arformoterol—Haematuria—Doxorubicin—kidney cancer	0.000194	0.000418	CcSEcCtD
Arformoterol—Abdominal pain—Paclitaxel—kidney cancer	0.000194	0.000418	CcSEcCtD
Arformoterol—Body temperature increased—Paclitaxel—kidney cancer	0.000194	0.000418	CcSEcCtD
Arformoterol—Headache—Vincristine—kidney cancer	0.000193	0.000417	CcSEcCtD
Arformoterol—Sinusitis—Doxorubicin—kidney cancer	0.000191	0.000412	CcSEcCtD
Arformoterol—Hypotension—Capecitabine—kidney cancer	0.000188	0.000406	CcSEcCtD
Arformoterol—Vomiting—Gemcitabine—kidney cancer	0.000186	0.000402	CcSEcCtD
Arformoterol—Rash—Gemcitabine—kidney cancer	0.000185	0.000398	CcSEcCtD
Arformoterol—Dermatitis—Gemcitabine—kidney cancer	0.000184	0.000398	CcSEcCtD
Arformoterol—Headache—Gemcitabine—kidney cancer	0.000183	0.000396	CcSEcCtD
Arformoterol—Nausea—Vincristine—kidney cancer	0.000183	0.000396	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Capecitabine—kidney cancer	0.000183	0.000395	CcSEcCtD
Arformoterol—Rhinitis—Doxorubicin—kidney cancer	0.000183	0.000395	CcSEcCtD
Arformoterol—Insomnia—Capecitabine—kidney cancer	0.000182	0.000393	CcSEcCtD
Arformoterol—Pharyngitis—Doxorubicin—kidney cancer	0.000181	0.000391	CcSEcCtD
Arformoterol—Hypersensitivity—Paclitaxel—kidney cancer	0.000181	0.00039	CcSEcCtD
Arformoterol—Urinary tract disorder—Doxorubicin—kidney cancer	0.00018	0.000389	CcSEcCtD
Arformoterol—Oedema peripheral—Doxorubicin—kidney cancer	0.00018	0.000388	CcSEcCtD
Arformoterol—Connective tissue disorder—Doxorubicin—kidney cancer	0.000179	0.000387	CcSEcCtD
Arformoterol—Dyspnoea—Capecitabine—kidney cancer	0.000179	0.000387	CcSEcCtD
Arformoterol—Urethral disorder—Doxorubicin—kidney cancer	0.000179	0.000386	CcSEcCtD
Arformoterol—Dyspepsia—Capecitabine—kidney cancer	0.000177	0.000382	CcSEcCtD
Arformoterol—Visual impairment—Doxorubicin—kidney cancer	0.000176	0.00038	CcSEcCtD
Arformoterol—Asthenia—Paclitaxel—kidney cancer	0.000176	0.00038	CcSEcCtD
Arformoterol—Nausea—Gemcitabine—kidney cancer	0.000174	0.000375	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Capecitabine—kidney cancer	0.000174	0.000375	CcSEcCtD
Arformoterol—Fatigue—Capecitabine—kidney cancer	0.000173	0.000374	CcSEcCtD
Arformoterol—Pruritus—Paclitaxel—kidney cancer	0.000173	0.000374	CcSEcCtD
Arformoterol—Pain—Capecitabine—kidney cancer	0.000172	0.000371	CcSEcCtD
Arformoterol—Constipation—Capecitabine—kidney cancer	0.000172	0.000371	CcSEcCtD
Arformoterol—Cardiac disorder—Doxorubicin—kidney cancer	0.000169	0.000366	CcSEcCtD
Arformoterol—Diarrhoea—Paclitaxel—kidney cancer	0.000168	0.000362	CcSEcCtD
Arformoterol—Feeling abnormal—Capecitabine—kidney cancer	0.000166	0.000358	CcSEcCtD
Arformoterol—Immune system disorder—Doxorubicin—kidney cancer	0.000165	0.000356	CcSEcCtD
Arformoterol—Gastrointestinal pain—Capecitabine—kidney cancer	0.000164	0.000355	CcSEcCtD
Arformoterol—Mediastinal disorder—Doxorubicin—kidney cancer	0.000164	0.000355	CcSEcCtD
Arformoterol—Arrhythmia—Doxorubicin—kidney cancer	0.000163	0.000352	CcSEcCtD
Arformoterol—Dizziness—Paclitaxel—kidney cancer	0.000162	0.00035	CcSEcCtD
Arformoterol—Mental disorder—Doxorubicin—kidney cancer	0.00016	0.000345	CcSEcCtD
Arformoterol—Urticaria—Capecitabine—kidney cancer	0.00016	0.000345	CcSEcCtD
Arformoterol—Abdominal pain—Capecitabine—kidney cancer	0.000159	0.000343	CcSEcCtD
Arformoterol—Body temperature increased—Capecitabine—kidney cancer	0.000159	0.000343	CcSEcCtD
Arformoterol—Malnutrition—Doxorubicin—kidney cancer	0.000159	0.000343	CcSEcCtD
Arformoterol—Tension—Doxorubicin—kidney cancer	0.000156	0.000336	CcSEcCtD
Arformoterol—Vomiting—Paclitaxel—kidney cancer	0.000156	0.000336	CcSEcCtD
Arformoterol—Dysgeusia—Doxorubicin—kidney cancer	0.000156	0.000336	CcSEcCtD
Arformoterol—Rash—Paclitaxel—kidney cancer	0.000155	0.000334	CcSEcCtD
Arformoterol—Dermatitis—Paclitaxel—kidney cancer	0.000154	0.000333	CcSEcCtD
Arformoterol—Nervousness—Doxorubicin—kidney cancer	0.000154	0.000333	CcSEcCtD
Arformoterol—Back pain—Doxorubicin—kidney cancer	0.000154	0.000332	CcSEcCtD
Arformoterol—Headache—Paclitaxel—kidney cancer	0.000154	0.000331	CcSEcCtD
Arformoterol—Muscle spasms—Doxorubicin—kidney cancer	0.000153	0.00033	CcSEcCtD
Arformoterol—Hypersensitivity—Capecitabine—kidney cancer	0.000148	0.00032	CcSEcCtD
Arformoterol—Ill-defined disorder—Doxorubicin—kidney cancer	0.000147	0.000318	CcSEcCtD
Arformoterol—Agitation—Doxorubicin—kidney cancer	0.000146	0.000315	CcSEcCtD
Arformoterol—Nausea—Paclitaxel—kidney cancer	0.000146	0.000314	CcSEcCtD
Arformoterol—Asthenia—Capecitabine—kidney cancer	0.000144	0.000311	CcSEcCtD
Arformoterol—Malaise—Doxorubicin—kidney cancer	0.000143	0.000309	CcSEcCtD
Arformoterol—Pruritus—Capecitabine—kidney cancer	0.000142	0.000307	CcSEcCtD
Arformoterol—Palpitations—Doxorubicin—kidney cancer	0.00014	0.000303	CcSEcCtD
Arformoterol—Cough—Doxorubicin—kidney cancer	0.000139	0.000299	CcSEcCtD
Arformoterol—Diarrhoea—Capecitabine—kidney cancer	0.000138	0.000297	CcSEcCtD
Arformoterol—Hypertension—Doxorubicin—kidney cancer	0.000137	0.000296	CcSEcCtD
Arformoterol—Chest pain—Doxorubicin—kidney cancer	0.000135	0.000292	CcSEcCtD
Arformoterol—Arthralgia—Doxorubicin—kidney cancer	0.000135	0.000292	CcSEcCtD
Arformoterol—Myalgia—Doxorubicin—kidney cancer	0.000135	0.000292	CcSEcCtD
Arformoterol—Anxiety—Doxorubicin—kidney cancer	0.000135	0.000291	CcSEcCtD
Arformoterol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.000134	0.00029	CcSEcCtD
Arformoterol—Discomfort—Doxorubicin—kidney cancer	0.000134	0.000288	CcSEcCtD
Arformoterol—Dizziness—Capecitabine—kidney cancer	0.000133	0.000287	CcSEcCtD
Arformoterol—Dry mouth—Doxorubicin—kidney cancer	0.000132	0.000285	CcSEcCtD
Arformoterol—Anaphylactic shock—Doxorubicin—kidney cancer	0.00013	0.00028	CcSEcCtD
Arformoterol—Oedema—Doxorubicin—kidney cancer	0.00013	0.00028	CcSEcCtD
Arformoterol—Infection—Doxorubicin—kidney cancer	0.000129	0.000278	CcSEcCtD
Arformoterol—Vomiting—Capecitabine—kidney cancer	0.000128	0.000276	CcSEcCtD
Arformoterol—Nervous system disorder—Doxorubicin—kidney cancer	0.000127	0.000274	CcSEcCtD
Arformoterol—Rash—Capecitabine—kidney cancer	0.000127	0.000274	CcSEcCtD
Arformoterol—Dermatitis—Capecitabine—kidney cancer	0.000127	0.000273	CcSEcCtD
Arformoterol—Tachycardia—Doxorubicin—kidney cancer	0.000127	0.000273	CcSEcCtD
Arformoterol—Headache—Capecitabine—kidney cancer	0.000126	0.000272	CcSEcCtD
Arformoterol—Skin disorder—Doxorubicin—kidney cancer	0.000126	0.000272	CcSEcCtD
Arformoterol—Hypotension—Doxorubicin—kidney cancer	0.000121	0.000261	CcSEcCtD
Arformoterol—Nausea—Capecitabine—kidney cancer	0.000119	0.000258	CcSEcCtD
Arformoterol—Musculoskeletal discomfort—Doxorubicin—kidney cancer	0.000118	0.000255	CcSEcCtD
Arformoterol—Insomnia—Doxorubicin—kidney cancer	0.000117	0.000253	CcSEcCtD
Arformoterol—Dyspnoea—Doxorubicin—kidney cancer	0.000116	0.000249	CcSEcCtD
Arformoterol—Somnolence—Doxorubicin—kidney cancer	0.000115	0.000249	CcSEcCtD
Arformoterol—Dyspepsia—Doxorubicin—kidney cancer	0.000114	0.000246	CcSEcCtD
Arformoterol—Gastrointestinal disorder—Doxorubicin—kidney cancer	0.000112	0.000242	CcSEcCtD
Arformoterol—Fatigue—Doxorubicin—kidney cancer	0.000112	0.000241	CcSEcCtD
Arformoterol—Constipation—Doxorubicin—kidney cancer	0.000111	0.000239	CcSEcCtD
Arformoterol—Pain—Doxorubicin—kidney cancer	0.000111	0.000239	CcSEcCtD
Arformoterol—Feeling abnormal—Doxorubicin—kidney cancer	0.000107	0.000231	CcSEcCtD
Arformoterol—Gastrointestinal pain—Doxorubicin—kidney cancer	0.000106	0.000229	CcSEcCtD
Arformoterol—Urticaria—Doxorubicin—kidney cancer	0.000103	0.000222	CcSEcCtD
Arformoterol—Abdominal pain—Doxorubicin—kidney cancer	0.000102	0.000221	CcSEcCtD
Arformoterol—Body temperature increased—Doxorubicin—kidney cancer	0.000102	0.000221	CcSEcCtD
Arformoterol—Hypersensitivity—Doxorubicin—kidney cancer	9.55e-05	0.000206	CcSEcCtD
Arformoterol—Asthenia—Doxorubicin—kidney cancer	9.3e-05	0.000201	CcSEcCtD
Arformoterol—Pruritus—Doxorubicin—kidney cancer	9.17e-05	0.000198	CcSEcCtD
Arformoterol—Diarrhoea—Doxorubicin—kidney cancer	8.87e-05	0.000191	CcSEcCtD
Arformoterol—Dizziness—Doxorubicin—kidney cancer	8.57e-05	0.000185	CcSEcCtD
Arformoterol—Vomiting—Doxorubicin—kidney cancer	8.24e-05	0.000178	CcSEcCtD
Arformoterol—Rash—Doxorubicin—kidney cancer	8.18e-05	0.000176	CcSEcCtD
Arformoterol—Dermatitis—Doxorubicin—kidney cancer	8.17e-05	0.000176	CcSEcCtD
Arformoterol—Headache—Doxorubicin—kidney cancer	8.12e-05	0.000175	CcSEcCtD
Arformoterol—Nausea—Doxorubicin—kidney cancer	7.7e-05	0.000166	CcSEcCtD
Arformoterol—CYP2A6—Metabolism—PGK1—kidney cancer	2.93e-05	0.00107	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.9e-05	0.00106	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PDHB—kidney cancer	2.89e-05	0.00105	CbGpPWpGaD
Arformoterol—CYP2C19—Biological oxidations—POMC—kidney cancer	2.88e-05	0.00105	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—ANXA1—kidney cancer	2.88e-05	0.00105	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—LDHB—kidney cancer	2.87e-05	0.00105	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—SFRP2—kidney cancer	2.75e-05	0.001	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CCBL1—kidney cancer	2.72e-05	0.00099	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—SFRP2—kidney cancer	2.69e-05	0.00098	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—ANXA1—kidney cancer	2.67e-05	0.000974	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PDHB—kidney cancer	2.66e-05	0.000969	CbGpPWpGaD
Arformoterol—CYP2D6—Biological oxidations—POMC—kidney cancer	2.65e-05	0.000966	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—kidney cancer	2.64e-05	0.000963	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PDHB—kidney cancer	2.63e-05	0.00096	CbGpPWpGaD
Arformoterol—CYP2C9—Biological oxidations—POMC—kidney cancer	2.63e-05	0.000957	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—ANXA1—kidney cancer	2.61e-05	0.000953	CbGpPWpGaD
Arformoterol—ADRB1—GPCR ligand binding—POMC—kidney cancer	2.55e-05	0.00093	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CCBL1—kidney cancer	2.5e-05	0.000911	CbGpPWpGaD
Arformoterol—ADRB2—GPCR ligand binding—POMC—kidney cancer	2.49e-05	0.000909	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CA9—kidney cancer	2.49e-05	0.000907	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CCBL1—kidney cancer	2.48e-05	0.000903	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.46e-05	0.000895	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GLIPR1—kidney cancer	2.35e-05	0.000858	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PPAT—kidney cancer	2.35e-05	0.000858	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.32e-05	0.000848	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.3e-05	0.000839	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—ACHE—kidney cancer	2.24e-05	0.000816	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—AKAP13—kidney cancer	2.21e-05	0.000807	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CASP2—kidney cancer	2.21e-05	0.000807	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—FH—kidney cancer	2.19e-05	0.000798	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—APRT—kidney cancer	2.19e-05	0.000798	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—AKAP13—kidney cancer	2.17e-05	0.00079	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CASP2—kidney cancer	2.17e-05	0.00079	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GLIPR1—kidney cancer	2.17e-05	0.00079	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PPAT—kidney cancer	2.17e-05	0.00079	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PPAT—kidney cancer	2.15e-05	0.000783	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GLIPR1—kidney cancer	2.15e-05	0.000783	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	2.14e-05	0.00078	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—SCARB1—kidney cancer	2.12e-05	0.000773	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CRABP1—kidney cancer	2.12e-05	0.000771	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—kidney cancer	2.1e-05	0.000765	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GPC3—kidney cancer	2.06e-05	0.00075	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—GRB7—kidney cancer	2.03e-05	0.000738	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—APRT—kidney cancer	2.01e-05	0.000734	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—FH—kidney cancer	2.01e-05	0.000734	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CA2—kidney cancer	2e-05	0.00073	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—FH—kidney cancer	2e-05	0.000728	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—APRT—kidney cancer	2e-05	0.000728	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—GRB7—kidney cancer	1.98e-05	0.000722	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ITPR2—kidney cancer	1.97e-05	0.000717	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ALAD—kidney cancer	1.95e-05	0.000711	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—kidney cancer	1.95e-05	0.000711	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ST3GAL2—kidney cancer	1.9e-05	0.000694	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GPC3—kidney cancer	1.89e-05	0.00069	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ITPR2—kidney cancer	1.88e-05	0.000687	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GPC3—kidney cancer	1.88e-05	0.000684	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ALDH1A1—kidney cancer	1.86e-05	0.000679	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ITPR2—kidney cancer	1.84e-05	0.000672	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CA2—kidney cancer	1.84e-05	0.000671	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CA2—kidney cancer	1.83e-05	0.000666	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALAD—kidney cancer	1.79e-05	0.000654	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTT1—kidney cancer	1.79e-05	0.000654	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ACHE—kidney cancer	1.79e-05	0.000654	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PGK1—kidney cancer	1.78e-05	0.000651	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SLC5A3—kidney cancer	1.78e-05	0.000651	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALAD—kidney cancer	1.78e-05	0.000649	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ST3GAL2—kidney cancer	1.75e-05	0.000639	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—LDHB—kidney cancer	1.75e-05	0.000638	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ST3GAL2—kidney cancer	1.74e-05	0.000633	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ALDH1A1—kidney cancer	1.71e-05	0.000624	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CTNNA1—kidney cancer	1.71e-05	0.000622	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—SCARB1—kidney cancer	1.7e-05	0.000619	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—EIF4EBP1—kidney cancer	1.7e-05	0.000619	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HSPB1—kidney cancer	1.7e-05	0.000619	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ALDH1A1—kidney cancer	1.7e-05	0.000619	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTGS1—kidney cancer	1.68e-05	0.000613	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CTNNA1—kidney cancer	1.67e-05	0.000609	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HSPB1—kidney cancer	1.66e-05	0.000605	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—EIF4EBP1—kidney cancer	1.66e-05	0.000605	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PSMD7—kidney cancer	1.65e-05	0.000601	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PGK1—kidney cancer	1.64e-05	0.000598	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SLC5A3—kidney cancer	1.64e-05	0.000598	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SLC5A3—kidney cancer	1.63e-05	0.000593	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PGK1—kidney cancer	1.63e-05	0.000593	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—LDHB—kidney cancer	1.61e-05	0.000587	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—LDHB—kidney cancer	1.6e-05	0.000582	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PSMD7—kidney cancer	1.58e-05	0.000575	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ANXA1—kidney cancer	1.58e-05	0.000575	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TSC1—kidney cancer	1.58e-05	0.000575	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—BCHE—kidney cancer	1.56e-05	0.00057	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—SLC5A5—kidney cancer	1.54e-05	0.000563	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TSC1—kidney cancer	1.54e-05	0.000563	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ANXA1—kidney cancer	1.54e-05	0.000563	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PSMD7—kidney cancer	1.54e-05	0.000563	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—FLT1—kidney cancer	1.53e-05	0.000557	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CA9—kidney cancer	1.52e-05	0.000553	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—FLT1—kidney cancer	1.49e-05	0.000545	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—SLC2A1—kidney cancer	1.49e-05	0.000544	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.48e-05	0.000541	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—POMC—kidney cancer	1.44e-05	0.000525	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JUNB—kidney cancer	1.42e-05	0.000516	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PAK1—kidney cancer	1.42e-05	0.000516	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—POMC—kidney cancer	1.41e-05	0.000514	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CA9—kidney cancer	1.4e-05	0.000509	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JUNB—kidney cancer	1.39e-05	0.000505	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PAK1—kidney cancer	1.39e-05	0.000505	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CA9—kidney cancer	1.38e-05	0.000504	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—kidney cancer	1.35e-05	0.000493	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—POMC—kidney cancer	1.31e-05	0.000477	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CRABP1—kidney cancer	1.29e-05	0.00047	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—POMC—kidney cancer	1.28e-05	0.000467	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTP1—kidney cancer	1.24e-05	0.000453	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ITPR2—kidney cancer	1.2e-05	0.000437	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CRABP1—kidney cancer	1.19e-05	0.000433	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—ABCB1—kidney cancer	1.18e-05	0.000429	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CRABP1—kidney cancer	1.18e-05	0.000429	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IGF2—kidney cancer	1.16e-05	0.000422	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN2B—kidney cancer	1.15e-05	0.00042	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—GSTM1—kidney cancer	1.14e-05	0.000417	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IGF2—kidney cancer	1.13e-05	0.000413	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN2B—kidney cancer	1.13e-05	0.000411	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IGF1R—kidney cancer	1.12e-05	0.000408	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.11e-05	0.000403	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ITPR2—kidney cancer	1.1e-05	0.000402	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IGF1R—kidney cancer	1.1e-05	0.000399	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ACHE—kidney cancer	1.09e-05	0.000399	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTT1—kidney cancer	1.09e-05	0.000399	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ITPR2—kidney cancer	1.09e-05	0.000399	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—CYP1A1—kidney cancer	1.08e-05	0.000395	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—RAF1—kidney cancer	1.08e-05	0.000393	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—IL2—kidney cancer	1.07e-05	0.000388	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—RAF1—kidney cancer	1.06e-05	0.000385	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—IL2—kidney cancer	1.04e-05	0.00038	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SCARB1—kidney cancer	1.04e-05	0.000377	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTGS1—kidney cancer	1.02e-05	0.000374	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—POMC—kidney cancer	1.01e-05	0.000368	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTT1—kidney cancer	1.01e-05	0.000367	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ACHE—kidney cancer	1.01e-05	0.000367	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PSMD7—kidney cancer	1.01e-05	0.000366	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ACHE—kidney cancer	9.97e-06	0.000364	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTT1—kidney cancer	9.97e-06	0.000364	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—IL2—kidney cancer	9.67e-06	0.000353	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—BCHE—kidney cancer	9.53e-06	0.000347	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SCARB1—kidney cancer	9.52e-06	0.000347	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—IL2—kidney cancer	9.46e-06	0.000345	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SCARB1—kidney cancer	9.44e-06	0.000344	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTGS1—kidney cancer	9.43e-06	0.000344	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SLC5A5—kidney cancer	9.41e-06	0.000343	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTGS1—kidney cancer	9.35e-06	0.000341	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PSMD7—kidney cancer	9.24e-06	0.000337	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—HIF1A—kidney cancer	9.22e-06	0.000336	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TSC2—kidney cancer	9.2e-06	0.000335	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PSMD7—kidney cancer	9.16e-06	0.000334	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—SLC2A1—kidney cancer	9.09e-06	0.000331	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—HIF1A—kidney cancer	9.02e-06	0.000329	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TSC2—kidney cancer	9e-06	0.000328	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.82e-06	0.000322	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KDR—kidney cancer	8.82e-06	0.000321	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—BCHE—kidney cancer	8.76e-06	0.00032	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—BCHE—kidney cancer	8.69e-06	0.000317	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SLC5A5—kidney cancer	8.66e-06	0.000316	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KDR—kidney cancer	8.62e-06	0.000314	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SLC5A5—kidney cancer	8.58e-06	0.000313	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—SLC2A1—kidney cancer	8.36e-06	0.000305	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—SLC2A1—kidney cancer	8.29e-06	0.000302	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—APC—kidney cancer	8.12e-06	0.000296	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KIT—kidney cancer	8.12e-06	0.000296	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—POMC—kidney cancer	8.08e-06	0.000294	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—kidney cancer	8.04e-06	0.000293	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KIT—kidney cancer	7.94e-06	0.00029	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—APC—kidney cancer	7.94e-06	0.00029	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—MAPK3—kidney cancer	7.78e-06	0.000284	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—POMC—kidney cancer	7.73e-06	0.000282	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.69e-06	0.00028	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—BRAF—kidney cancer	7.63e-06	0.000278	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—MAPK3—kidney cancer	7.61e-06	0.000277	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTP1—kidney cancer	7.58e-06	0.000276	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—POMC—kidney cancer	7.56e-06	0.000276	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—BRAF—kidney cancer	7.47e-06	0.000272	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—MAPK1—kidney cancer	7.4e-06	0.00027	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—MAPK1—kidney cancer	7.24e-06	0.000264	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—ABCB1—kidney cancer	7.18e-06	0.000262	CbGpPWpGaD
Arformoterol—ADRB1—GPCR downstream signaling—PIK3CA—kidney cancer	7.07e-06	0.000258	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—kidney cancer	7.01e-06	0.000256	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—KRAS—kidney cancer	6.99e-06	0.000255	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTP1—kidney cancer	6.97e-06	0.000254	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—GSTM1—kidney cancer	6.97e-06	0.000254	CbGpPWpGaD
Arformoterol—ADRB2—GPCR downstream signaling—PIK3CA—kidney cancer	6.92e-06	0.000252	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTP1—kidney cancer	6.91e-06	0.000252	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—KRAS—kidney cancer	6.84e-06	0.000249	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—CYP1A1—kidney cancer	6.6e-06	0.000241	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—ABCB1—kidney cancer	6.6e-06	0.000241	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—ABCB1—kidney cancer	6.54e-06	0.000239	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTGS2—kidney cancer	6.44e-06	0.000235	CbGpPWpGaD
Arformoterol—ADRB1—Signaling by GPCR—PIK3CA—kidney cancer	6.42e-06	0.000234	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—GSTM1—kidney cancer	6.41e-06	0.000234	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RAF1—kidney cancer	6.37e-06	0.000232	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—GSTM1—kidney cancer	6.35e-06	0.000232	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—RELA—kidney cancer	6.35e-06	0.000231	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—ERBB2—kidney cancer	6.31e-06	0.00023	CbGpPWpGaD
Arformoterol—ADRB2—Signaling by GPCR—PIK3CA—kidney cancer	6.28e-06	0.000229	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RAF1—kidney cancer	6.24e-06	0.000227	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MTOR—kidney cancer	6.22e-06	0.000227	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—RELA—kidney cancer	6.21e-06	0.000226	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—ERBB2—kidney cancer	6.17e-06	0.000225	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MTOR—kidney cancer	6.09e-06	0.000222	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—CYP1A1—kidney cancer	6.07e-06	0.000221	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—CYP1A1—kidney cancer	6.02e-06	0.00022	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CDKN1B—kidney cancer	5.84e-06	0.000213	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—IL2—kidney cancer	5.72e-06	0.000208	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CDKN1B—kidney cancer	5.71e-06	0.000208	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PTEN—kidney cancer	5.62e-06	0.000205	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—IL2—kidney cancer	5.59e-06	0.000204	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CCND1—kidney cancer	5.57e-06	0.000203	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—JUN—kidney cancer	5.56e-06	0.000203	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—CTNNB1—kidney cancer	5.52e-06	0.000201	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CCND1—kidney cancer	5.45e-06	0.000199	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—JUN—kidney cancer	5.44e-06	0.000198	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	5.43e-06	0.000198	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—CTNNB1—kidney cancer	5.4e-06	0.000197	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PTEN—kidney cancer	5.38e-06	0.000196	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PTEN—kidney cancer	5.26e-06	0.000192	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—kidney cancer	4.95e-06	0.00018	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—POMC—kidney cancer	4.92e-06	0.00018	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—VEGFA—kidney cancer	4.86e-06	0.000177	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—VEGFA—kidney cancer	4.75e-06	0.000173	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK3—kidney cancer	4.59e-06	0.000168	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—POMC—kidney cancer	4.53e-06	0.000165	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK3—kidney cancer	4.49e-06	0.000164	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—POMC—kidney cancer	4.49e-06	0.000164	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MYC—kidney cancer	4.47e-06	0.000163	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—MAPK1—kidney cancer	4.37e-06	0.000159	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MYC—kidney cancer	4.37e-06	0.000159	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—MAPK1—kidney cancer	4.28e-06	0.000156	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—KRAS—kidney cancer	4.13e-06	0.000151	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—KRAS—kidney cancer	4.04e-06	0.000147	CbGpPWpGaD
Arformoterol—CYP2A6—Metabolism—PIK3CA—kidney cancer	3.96e-06	0.000144	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTGS2—kidney cancer	3.93e-06	0.000143	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—PIK3CA—kidney cancer	3.79e-06	0.000138	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—PIK3CA—kidney cancer	3.71e-06	0.000135	CbGpPWpGaD
Arformoterol—ADRB1—Signaling Pathways—TP53—kidney cancer	3.67e-06	0.000134	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTGS2—kidney cancer	3.61e-06	0.000132	CbGpPWpGaD
Arformoterol—ADRB2—Signaling Pathways—TP53—kidney cancer	3.59e-06	0.000131	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTGS2—kidney cancer	3.58e-06	0.000131	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PTEN—kidney cancer	3.43e-06	0.000125	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PTEN—kidney cancer	3.15e-06	0.000115	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PTEN—kidney cancer	3.12e-06	0.000114	CbGpPWpGaD
Arformoterol—CYP2C19—Metabolism—PIK3CA—kidney cancer	2.42e-06	8.81e-05	CbGpPWpGaD
Arformoterol—CYP2D6—Metabolism—PIK3CA—kidney cancer	2.22e-06	8.1e-05	CbGpPWpGaD
Arformoterol—CYP2C9—Metabolism—PIK3CA—kidney cancer	2.2e-06	8.03e-05	CbGpPWpGaD
